EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Mechanism‐Based Multi‐Level Population PK/PD Model for Potassium‐Competitive Acid Blockers

Woojin Jung iD, Jaeyeon Lee iD, Hyeseon Jeon iD, Taewook Sung, Hwi-Yeol Yun iD, Soyoung Lee iD, Jung-Woo Chae iD

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Woojin Jung und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Models, Biological, Proton Pump Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chungnam National University, Institute of Information & Communications Technology Planning Evaluation (IITP), National Research Foundation of Korea (NRF), Core Technology Development Project for Environmental Diseases Prevention and Management.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Potassium‐competitive acid blockers (PCABs) are emerging alternatives to proton pump inhibitors for the treatment of acid‐related diseases. However, due to the complex, nonlinear interaction between drug exposure, food intake, and physiological rhythms, optimizing dosing strategies remains challenging. A multi‐leveled population analysis was conducted using published pharmacokinetic and pharmacodynamic data on four representative PCABs: tegoprazan, YH4808, fexuprazan, and vonoprazan. A semi‐mechanistic population PK/PD model was developed to account for food effects, circadian pH rhythms, and pH‐dependent drug absorption. A multi‐level nonlinear mixed‐effects modeling framework was implemented to capture both inter‐drug and inter‐study variability. The model successfully described the time course of plasma concentration and intragastric pH for all four PCABs under various conditions. The model identified differences in pharmacokinetics and pharmacodynamic potency between drugs (with the relative in vitro potency ranked as vonoprazan > fexuprazan > YH4808 > tegoprazan), and simulations demonstrated that both pre‐ and post‐meal administration enhanced pH control in early time period via potentially distinct mechanisms: the pre‐meal effect may arise from temporally separated contributions of food‐ and drug‐induced pH elevation, whereas the post‐meal effect is likely driven by temporally overlapping, additive actions, particularly under low‐dose or non‐steady‐state conditions. Predicted pH profiles and holding times above pH 4 closely matched reported clinical outcomes. The study demonstrates the application of a mechanistic, multi‐level population approach for cross‐drug PK/PD evaluation of PCABs. The findings support drug‐specific dose optimization and highlight the clinical relevance of food–drug interactions. The modeling approach provides a model platform for pharmacotherapy or model‐informed drug development (MIDD).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalProton Pump InhibitorsHumansPyrrolesHydrogen-Ion ConcentrationFood-Drug InteractionsSulfonamidesCircadian RhythmPotassiumBenzene DerivativesImidazoles

Stichwörter der Autor:innen

anti‐ulcer agentmulti‐level population analysispharamcodynamicspharmacokineticspharmacometrics

Substanzen

vonoprazanPyrrolesProton Pump InhibitorsSulfonamidestegoprazanPotassiumBenzene DerivativesImidazoles

Autor:innen und Institutionen

  • College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon, Republic of Korea.
  • Senior Health Convergence Research Center, Chungnam National University, Daejeon, Republic of Korea.
  • Clinical Pharmacology Team, Clinical Science Group, Clinical Development and Medical Division, Yuhan Corporation, Seoul, Republic of Korea.
  • Department of Bio-AI Convergence, Chungnam National University, Daejeon, Republic of Korea.

ORCID-Profile: Woojin Jung, Jaeyeon Lee, Hyeseon Jeon, Hwi-Yeol Yun, Soyoung Lee, Jung-Woo Chae

Förderung

  • Chungnam National University, Institute of Information & Communications Technology Planning Evaluation (IITP)
  • National Research Foundation of Korea (NRF)
  • Core Technology Development Project for Environmental Diseases Prevention and Management
  • Korea Ministry of Environment (MOE)
  • Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea
  • Korea Institute of Toxicology (KIT) Research Program
  • Ministry of Health & Welfare, Republic of Korea
  • Ministry of Trade, Industry, and Energy (MOTIE)

Zitieren

APA

Jung, W., Lee, J., Jeon, H., Sung, T., Yun, H. Y., Lee, S., & Chae, J. W. (2026). A Mechanism‐Based Multi‐Level Population PK/PD Model for Potassium‐Competitive Acid Blockers. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70181

Vancouver

Jung W, Lee J, Jeon H, Sung T, Yun HY, Lee S, et al. A Mechanism‐Based Multi‐Level Population PK/PD Model for Potassium‐Competitive Acid Blockers. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70181

BibTeX
@article{Jung2026,
  author = {Jung, Woojin and Lee, Jaeyeon and Jeon, Hyeseon and Sung, Taewook and Yun, Hwi-Yeol and Lee, Soyoung and Chae, Jung-Woo},
  title = {A Mechanism‐Based Multi‐Level Population PK/PD Model for Potassium‐Competitive Acid Blockers},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70181}
}
Kostenlos starten →